Patents Assigned to Genentech
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20080292631
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: July 25, 2008
    Publication date: November 27, 2008
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20080292630
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: July 15, 2008
    Publication date: November 27, 2008
    Applicant: GENENTECH, INC.
    Inventors: GWENDOLYN FYFE, ERIC HOLMGREN, ROBERT D. MASS, WILLIAM NOVOTNY
  • HUMAN DNASE I HYPERACTIVE VARIANTS
    Publication number: 20080293121
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
    Type: Application
    Filed: July 1, 2008
    Publication date: November 27, 2008
    Applicant: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • PRO9830 antibodies
    Patent number: 7456261
    Abstract: The present invention is directed to antibodies which bind to PRO9830 polypeptides.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: November 25, 2008
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Luc Desnoyers, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean-Philippe F. Stephan, Colin K. Watanabe, William I. Wood
  • Methods and composition for modulating and detecting wisp activity
    Patent number: 7456262
    Abstract: Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of IIAS2, IIA, CD44 or RIIAMM by native human WISP-1 polypeptide in at least one type of cells or pathological conditions associated with native WISP-1 polypeptides.
    Type: Grant
    Filed: June 28, 2003
    Date of Patent: November 25, 2008
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Ellen Filvaroff
  • Methods and compositions for modulating and detecting WISP activity
    Patent number: 7455834
    Abstract: Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell. The invention also provides methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with native WISP-1 polypeptides.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: November 25, 2008
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyer, Ellen Filvaroff
  • Stabilizing polypeptides which have been exposed to urea
    Patent number: 7452539
    Abstract: Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: November 18, 2008
    Assignee: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona M. O'Leary
  • Anti-PRO7168 antibodies
    Patent number: 7452975
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: November 18, 2008
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong
  • NGF variants
    Patent number: 7452863
    Abstract: NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: November 18, 2008
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, Roman Urfer, John W. Winslow
  • Treatment With Anti-VEGF Antibodies
    Publication number: 20080279860
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: May 27, 2008
    Publication date: November 13, 2008
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • Methods of treating lupus using CD4 antibodies
    Publication number: 20080279848
    Abstract: Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody that results in an improvement in renal function and/or a reduction in proteinuria or active urinary sediment are also provided. Methods of treating lupus or decreasing autoantibody titer by administration of a non-depleting CD4 antibody are also provided. Methods of treating multiple sclerosis by administration of a non-depleting CD4 antibody, optionally in combination with another compound used clinically or experimentally to treat MS, are described. Methods of treating transplant recipients and subjects with rheumatoid arthritis, asthma, psoriasis, Crohn's disease, ulcerative colitis, and Sjogren's syndrome are also provided.
    Type: Application
    Filed: March 20, 2008
    Publication date: November 13, 2008
    Applicant: GENENTECH, INC.
    Inventor: Bryan Irving
  • Fibroblast Activation Protein Inhibitor Compounds and Methods
    Publication number: 20080280856
    Abstract: Amino terminus-blocked peptide boronate compounds of Formulas I and II are useful for inhibiting Fibroblast Activation Protein (FAP) and other proteases, and for treating disorders mediated by FAP. Methods of using the amino terminus blocked peptide boronate compounds, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: June 4, 2008
    Publication date: November 13, 2008
    Applicant: Genentech, Inc.
    Inventors: Frederick Cohen, Wayne J. Fairbrother, Clifford Quan, Daniel P. Sutherlin, Beni B. Wolf
  • Fixed dosing of HER antibodies
    Patent number: 7449184
    Abstract: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: November 11, 2008
    Assignee: Genentech, Inc.
    Inventors: David E. Allison, Rene Bruno, Jian-Feng Lu, Chee M. Ng
  • Treatment of inflammatory bowel disease with IFN-? inhibitors
    Patent number: 7449176
    Abstract: The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-? inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: November 11, 2008
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Rebecca H. R. Ward
  • PRO211 polypeptides
    Patent number: 7449551
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: November 11, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Paul J. Godowski, William I. Wood, Napoleone Ferrara
  • Antibodies against the PRO4977 polypeptides
    Patent number: 7449554
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: November 11, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • PRO9822 polypeptides
    Patent number: 7449549
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: November 11, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION
    Publication number: 20080274506
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Application
    Filed: February 19, 2008
    Publication date: November 6, 2008
    Applicant: Genentech, Inc.
    Inventor: LEONARD PRESTA
  • POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION
    Publication number: 20080274105
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Application
    Filed: November 16, 2007
    Publication date: November 6, 2008
    Applicant: Genentech, Inc.
    Inventor: LEONARD PRESTA
  • POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION
    Publication number: 20080274108
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Application
    Filed: July 11, 2008
    Publication date: November 6, 2008
    Applicant: Genentech, Inc.
    Inventor: LEONARD PRESTA